|1.||Hagino, Hiroshi: 5 articles (09/2013 - 06/2009)|
|2.||Nishida, Shozo: 5 articles (03/2012 - 01/2003)|
|3.||Nakamura, Toshitaka: 4 articles (09/2013 - 03/2005)|
|4.||Fukunaga, Masao: 4 articles (09/2013 - 01/2009)|
|5.||Tsubaki, Masanobu: 4 articles (03/2012 - 10/2003)|
|6.||Maekawa, Taira: 4 articles (07/2006 - 01/2005)|
|7.||Kimura, Shinya: 4 articles (07/2006 - 01/2005)|
|8.||Segawa, Hidekazu: 4 articles (07/2006 - 01/2005)|
|9.||Yuasa, Takeshi: 4 articles (07/2006 - 01/2005)|
|10.||Nogawa, Masaki: 4 articles (07/2006 - 01/2005)|
01/01/2010 - "Daily oral minodronate was safe, well tolerated and effective in reducing vertebral fracture risk in postmenopausal women with established osteoporosis. "
09/01/2009 - "Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis."
08/01/2009 - "Daily oral minodronate is safe, well-tolerated, and is effective in reducing vertebral fracture risk in postmenopausal women with established osteoporosis."
08/01/2009 - "Minodronate is a safe and effective bisphosphonate for osteoporosis treatment. "
09/01/2013 - "Number and severity of prevalent vertebral fractures and the risk of subsequent vertebral fractures in Japanese women with osteoporosis: results from the minodronate trial."
|2.||Neoplasm Metastasis (Metastasis)
08/01/2015 - "Combined treatment with YM529 and IFN-α may be beneficial in patients with human RCC bone metastasis. "
01/01/2003 - "In addition, treatment with YM529 after establishment of bone metastasis (on day 21) also inhibited bone metastasis, although the treatment was more effective when started earlier. "
03/15/2012 - "The results indicated that YM529/ONO-5920 suppressed the Ras/MEK/ERK and Ras/PI3K/Akt pathways, thereby inhibiting LM8 cell migration, invasion, adhesion, and metastasis. "
03/15/2012 - "We found that YM529/ONO-5920 significantly inhibited metastasis, cell migration, invasion, and adhesion at concentrations that did not have antiproliferative effects on LM8 cells. "
10/01/2010 - "These findings suggest that YM529/ONO-5920 has potential clinical applications for the treatment of tumour cell metastasis."
08/08/2007 - "These results suggest that YM529 is a potent therapeutic agent for human breast cancers, activating the mitochondria-dependent apoptotic pathway through the inhibition of protein farnesylation."
01/01/2007 - "Our study demonstrate that YM529 showed direct anti-tumor effect on NSCLC cell lines in vitro, which supports the possibility that third-generation BPs including YM529 can be one of therapeutic options for NSCLC."
06/01/2006 - "The purpose of this study was to investigate the antitumor effects of newly developed minodronate (MIN) on a variety of human malignant bone tumors. "
08/01/2015 - "Neither YM529 nor IFN-α alone significantly inhibited the growth of established bone metastatic tumors. "
06/15/2007 - "Histomorphometric analysis revealed that YM529 markedly inhibited both the formation of bone tumors and the progression of established tumors, as well as markedly reducing the number of osteoclasts. "
|4.||Hip Fractures (Intertrochanteric Fractures)
09/01/2013 - "Non-vertebral fractures occurred in 5 patients in the minodronate group and 7 patients in the risedronate group (5 hip fractures; one fracture each at the distal forearm and pelvis). "
03/01/2010 - "In postmenopausal women with osteoporosis, alendronate, risedronate, minodronate, and raloxifene are effective in preventing vertebral fractures, and alendronate and risedronate significantly prevent hip fractures. "
03/01/2012 - "In conclusion, the present review confirmed the efficacy of etidronate, minodronate and raloxifene for the prevention of vertebral fractures, the efficacy of alendronate for vertebral and hip fractures, and the efficacy of risedronate for vertebral, nonvertebral and hip fractures in Japanese patients with an increased fracture risk."
07/01/2012 - "The objective of this study was to determine the safety and efficacy of long-term minodronate treatment in women with postmenopausal osteoporosis based on re-analysis of a phase III 2-year clinical trial with a 1-year extension. "
07/01/2012 - "Three years of treatment with minodronate in patients with postmenopausal osteoporosis."
05/01/2010 - "Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis."
06/01/2009 - "A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis."
03/01/2013 - "The purpose of the present study was to precisely compare both the efficacy and abdominal symptom-related quality of life after treatment with daily minodronate and weekly alendronate in patients with primary postmenopausal osteoporosis. "
|1.||Alendronate (Alendronate Sodium)
|3.||risedronic acid (risedronate)
|6.||Etidronic Acid (HEDP)
|7.||Protein Kinases (Protein Kinase)
|8.||Immunosuppressive Agents (Immunosuppressants)
|3.||Drug Therapy (Chemotherapy)